292 related articles for article (PubMed ID: 21914504)
1. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib.
Casciano R; Chulikavit M; Di Lorenzo G; Liu Z; Baladi JF; Wang X; Robertson J; Garrison L
Value Health; 2011; 14(6):846-51. PubMed ID: 21914504
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.
Mihajlović J; Pechlivanoglou P; Sabo A; Tomić Z; Postma MJ
Clin Ther; 2013 Dec; 35(12):1909-22. PubMed ID: 24238790
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.
Casciano R; Chulikavit M; Perrin A; Liu Z; Wang X; Garrison LP
J Med Econ; 2012; 15 Suppl 1():55-64. PubMed ID: 22881362
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma.
Hoyle M; Green C; Thompson-Coon J; Liu Z; Welch K; Moxham T; Stein K
Value Health; 2010; 13(1):55-60. PubMed ID: 19804431
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.
Calvo Aller E; Maroto P; Kreif N; González Larriba JL; López-Brea M; Castellano D; Martí B; Díaz Cerezo S
Clin Transl Oncol; 2011 Dec; 13(12):869-77. PubMed ID: 22126730
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.
Remák E; Charbonneau C; Négrier S; Kim ST; Motzer RJ
J Clin Oncol; 2008 Aug; 26(24):3995-4000. PubMed ID: 18711190
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations.
Norum J; Nieder C; Kondo M
J Chemother; 2010 Apr; 22(2):75-82. PubMed ID: 20435564
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
Benedict A; Figlin RA; Sandström P; Harmenberg U; Ullén A; Charbonneau C; Sandin R; Remák E; Hariharan S; Négrier S
BJU Int; 2011 Sep; 108(5):665-72. PubMed ID: 21265994
[TBL] [Abstract][Full Text] [Related]
9. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.
Di Lorenzo G; Casciano R; Malangone E; Buonerba C; Sherman S; Willet J; Wang X; Liu Z; De Placido S
Expert Opin Pharmacother; 2011 Jul; 12(10):1491-7. PubMed ID: 21599551
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.
Carr BI; Carroll S; Muszbek N; Gondek K
J Gastroenterol Hepatol; 2010 Nov; 25(11):1739-46. PubMed ID: 21039835
[TBL] [Abstract][Full Text] [Related]
11. Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis.
Pitt M; Crathorne L; Moxham T; Bond M; Hyde C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):41-6. PubMed ID: 21047490
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
[TBL] [Abstract][Full Text] [Related]
13. Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US.
Perrin A; Sherman S; Pal S; Chua A; Gorritz M; Liu Z; Wang X; Culver K; Casciano R; Garrison LP
J Med Econ; 2015 Mar; 18(3):200-9. PubMed ID: 25422989
[TBL] [Abstract][Full Text] [Related]
14. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Kay A; Ravaud A;
Cancer; 2010 Sep; 116(18):4256-65. PubMed ID: 20549832
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
Purmonen T; Martikainen JA; Soini EJ; Kataja V; Vuorinen RL; Kellokumpu-Lehtinen PL
Clin Ther; 2008 Feb; 30(2):382-92. PubMed ID: 18343276
[TBL] [Abstract][Full Text] [Related]
16. [Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma].
Ondrácková B; Demlová R; Komínek J
Klin Onkol; 2010; 23(6):439-45. PubMed ID: 21351422
[TBL] [Abstract][Full Text] [Related]
17. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.
De Groot S; Blommestein HM; Redekop WK; Sleijfer S; Kiemeney LALM; Oosterwijk E; Uyl-de Groot CA
PLoS One; 2017; 12(5):e0177364. PubMed ID: 28531203
[TBL] [Abstract][Full Text] [Related]
18. A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System.
Paz-Ares L; del Muro JG; Grande E; Díaz S
J Clin Pharm Ther; 2010 Aug; 35(4):429-38. PubMed ID: 20831545
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]